Astepro approved in Europe

Astepro approved in Europe

Astepro has received registration approval in Europe via the decentralized
procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis.
National registration processes, including price and reimbursement, will now
follow in each country. Launch is expected next year.

"We are pleased to announce the approval of Astepro in Europe. The product has
been launched in the US with good success. With the addition of Dymista
(currently in registration phase) Meda will have an extraordinary strong
position in the allergy rhinitis area, both in the US and Europe", said Anders
Lönner, CEO of Meda AB.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46 709-458 878